Lipvas 20 Tablet contains Atorvastatin 20mg, a lipid-lowering agent belonging to the statin class. It is primarily indicated for the treatment of hypercholesterolemia and mixed dyslipidemia to reduce elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and triglycerides, while increasing high-density lipoprotein cholesterol (HDL-C). Atorvastatin exerts its effect by selectively inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to decreased cholesterol production in the liver and increased clearance of LDL from the bloodstream. Lipvas 20 is prescribed to reduce the risk of cardiovascular events such as myocardial infarction, stroke, and the need for coronary revascularization in patients with atherosclerotic cardiovascular disease or those at high risk due to multiple risk factors. The tablet is administered orally, typically once daily, with or without food, and dosage adjustments should be individualized based on patient response and tolerability. Common adverse effects may include headache, myalgia, and gastrointestinal disturbances. Liver function tests and lipid profiles should be monitored periodically during therapy. Lipvas 20 should be used cautiously in patients with hepatic impairment, and contraindicated during pregnancy and lactation. It is essential to combine therapy with lifestyle modifications including diet, exercise, and weight control for optimal therapeutic outcomes.